Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
2021 · Journal for ImmunoTherapy of Cancer · 65 citations
https://doi.org/10.1136/jitc-2021-002488
R
Rong Deng
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
121
Papers
3.2K
Citations
31
h-index
54
i10-index
Rong Deng is an academic researcher from Shenyang Pharmaceutical University. The author has contributed to research in topics: Monoclonal and Polyclonal Antibodies Research & Protein purification and stability & HER2/EGFR in Cancer Research. The author has an h-index of 31, co-authored 103 publications.
ORCID: 0000-0003-2005-7517Papers by this author
worksTranslational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study
2010 · Clinical Pharmacology & Therapeutics · 45 citations
https://doi.org/10.1038/clpt.2010.311
Dynamics of NK, CD8 and Tfh cell mediated the production of cytokines and antiviral antibodies in Chinese patients with moderate COVID‐19
2020 · Journal of Cellular and Molecular Medicine · 34 citations
https://doi.org/10.1111/jcmm.16044
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
2021 · Cancer Chemotherapy and Pharmacology · 14 citations
https://doi.org/10.1007/s00280-021-04296-0
The effectiveness and safety of acupuncture in the treatment of lumbar disc herniation
2020 · Medicine · 7 citations
https://doi.org/10.1097/md.0000000000018930
A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
2024 · Clinical Pharmacology & Therapeutics · 6 citations
https://doi.org/10.1002/cpt.3445
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat